Vizsgálati helyszín

START Mountain Region

West Valley City, Utah 84119, Egyesült ÁllamokMég nincs intézményhez kötve

40futó vizsgálat
9lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 49 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Tüdőrák32 vizsgálat
Vastagbélrák18 vizsgálat
Petefészekrák17 vizsgálat
Hasnyálmirigyrák15 vizsgálat
Tripla negatív emlőrák14 vizsgálat
Gyomor- és nyelőcsőrák13 vizsgálat
Prosztatarák11 vizsgálat
Fej-nyaki daganatok10 vizsgálat
Méhnyakrák9 vizsgálat
Méhtestrák9 vizsgálat
Hólyagrák8 vizsgálat
Melanóma7 vizsgálat
és még 10
Fázis: 1. fázis27 vizsgálat
1/2. fázis18 vizsgálat
2. fázis4 vizsgálat
Állapot: Toboroz30 vizsgálat
Fut, nem toboroz8 vizsgálat
Leállították6 vizsgálat
Lezárult3 vizsgálat
Meghívásos bevonás1 vizsgálat
Még nem toboroz1 vizsgálat
Fő szponzor: Eli Lilly and Company6 vizsgálat
Pfizer3 vizsgálat
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.2 vizsgálat
Janssen Research & Development, LLC2 vizsgálat
Lantern Pharma Inc.2 vizsgálat
és még 32

Futó vizsgálatok

Még nem toboroz
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361· 2. fázis· Monte Rosa Therapeutics, Inc· Forrás
Contact: Monte Rosa Therapeutics Sponsor
Toboroz
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713· 1. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· 2. fázis· Verastem, Inc.· Forrás
Contact: START Hope Team
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· 2. fázis· Verastem, Inc.· Forrás
Contact: HOPE Team
Toboroz
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676· 1/2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Contact: Astellas Pharma Global Development, Inc
Toboroz
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198· 1. fázis· Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.· Forrás
Contact: Exscientia AI Ltd.
Toboroz
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· 1/2. fázis· TRIANA Biomedicines, Inc.· Forrás
Contact: HOPE Team
Toboroz
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562· 1. fázis· Cogent Biosciences, Inc.· Forrás
Contact: Cogent Biosciences, Inc
Toboroz
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805· 1. fázis· Pfizer· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047· 1/2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150· 1. fázis· PAQ Therapeutics, Inc.· Forrás
Contact: William McKean
Meghívásos bevonás
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003· 1. fázis· Rondo Therapeutics· Forrás
Toboroz
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT07190469· 1. fázis· ProteinQure Inc.· Forrás
Contact: Olivia Darais
Toboroz
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255· 1/2. fázis· MBrace Therapeutics· Forrás
Contact: William B McKean, MD, PhD
Toboroz
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257· 1/2. fázis· Tasca Therapeutics· Forrás
Contact: Marie Asay
Toboroz
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549· 1. fázis· ModernaTX, Inc.· Forrás
Contact: Moderna WeCare Team
Toboroz
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193· 1. fázis· Olema Pharmaceuticals, Inc.· Forrás
Contact: There may be multiple sites in this clinical trial Olema Clinical Trial Lead
Toboroz
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659· 1/2. fázis· Recursion Pharmaceuticals Inc.· Forrás
Contact: Marie Asay
Toboroz
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· 1/2. fázis· Gilead Sciences· Forrás
Toboroz
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472· 1. fázis· Eli Lilly and Company· Forrás
Contact: William McKean (principal investigator)
Toboroz
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871· 1. fázis· Iambic Therapeutics, Inc· Forrás
Contact: Iambic Therapeutics, Inc., Senior Medical Director
Toboroz
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470· 1. fázis· MacroGenics· Forrás
Contact: Global Trial Manager
Fut, nem toboroz
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· 1. fázis· Vividion Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121· 1. fázis· Adcentrx Therapeutics· Forrás
Toboroz
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706· 1. fázis· Pliant Therapeutics, Inc.· Forrás
Contact: Pliant Therapeutics Medical Monitor
Toboroz
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655· 1/2. fázis· Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.· Forrás
Contact: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Fut, nem toboroz
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265· 1/2. fázis· Lantern Pharma Inc.· Forrás
Fut, nem toboroz
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587· 1. fázis· IDEAYA Biosciences· Forrás
Toboroz
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139· 1/2. fázis· Eli Lilly and Company· Forrás
Contact: William McKean (principal investigator)
Toboroz
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503· 1. fázis· Lantern Pharma Inc.· Forrás
Contact: Marie Asay
Toboroz
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366· 1/2. fázis· Genmab· Forrás
Toboroz
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762· 1. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714· 1/2. fázis· Treadwell Therapeutics, Inc· Forrás
Fut, nem toboroz
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640· 1/2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
NCT04577833· 1. fázis· Janssen Research & Development, LLC· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Leállították
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
NCT06546553· 1. fázis· Pfizer· Forrás
Leállították
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696· 1. fázis· Astellas Pharma Inc· Forrás
Leállították
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NCT06264921· 1. fázis· NiKang Therapeutics, Inc.· Forrás
Toboroz
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771· 1/2. fázis· Frontier Medicines Corporation· Forrás
Contact: Medical Lead
Lezárult
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011· 2. fázis· MacroGenics· Forrás
Lezárult
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144· 1/2. fázis· Sensei Biotherapeutics, Inc.· Forrás
Leállították
A Study of SGN-ALPV in Advanced Solid Tumors
NCT05229900· 1. fázis· Seagen Inc.· Forrás
Leállították
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877· 1/2. fázis· Merus B.V.· Forrás
Leállították
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624· 1. fázis· Inhibrx Biosciences, Inc· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 14.

Hibát jelzek